Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy.
暂无分享,去创建一个
Q. Ning | J. Niu | Hong Tang | Xinyue Chen | H. Ren | J. Sheng | Yanyan Yu | Mao-rong Wang | Jun Cheng | M. Wan | Zhiliang Gao | Jian Sun | J. Hou | D. Tan | Q. Xie | Hong Ma | Shi Liu | Min Xu | X. Dou | Bin Zhou | Jie Peng | R. Fan | Hao Wang | Shijun Chen | Hongfei Zhang | G. Shi | X. Bai | Feng Lu | Huimin Liu | J. Niu
[1] M. Otsuka,et al. Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction , 2018, Cellular and molecular gastroenterology and hepatology.
[2] T. Berg,et al. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B , 2018, The Journal of infectious diseases.
[3] Y. Liaw,et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.
[4] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[5] Lanjuan Li,et al. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update) , 2017, Journal of clinical and translational hepatology.
[6] Thomas Berg,et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.
[7] H. Janssen,et al. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study , 2017, The Journal of infectious diseases.
[8] J. Niu,et al. Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity": Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B. , 2017, Journal of hepatology.
[9] T. Volz,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. , 2017, Journal of hepatology.
[10] N. Xia,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. , 2016, Journal of hepatology.
[11] E. Cholongitas,et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review , 2016, Hepatology.
[12] N. Kootstra,et al. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues. , 2016, The Journal of infectious diseases.
[13] M. Kumar,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.
[14] K. Chayama,et al. On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy , 2015, Antiviral therapy.
[15] T. Berg,et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors , 2015, Hepatology.
[16] Q. Ning,et al. The 104‐week efficacy and safety of telbivudine‐based optimization strategy in chronic hepatitis B patients: A randomized, controlled study , 2014, Hepatology.
[17] V. Wong,et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.
[18] John F. Flaherty,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.
[19] M. Imamura,et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients , 2013, Journal of Gastroenterology.
[20] Jia-Horng Kao,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.
[21] Ching-Lung Lai,et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.
[22] C. Gibbs,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.